New in-depth article explores the future of patient-reported outcomes (PROs)

Share on: 

Will FDA's patient-centered drug development initiatives increase the prevalence of patient-reported outcomes (PRO) research during early phases of drug development?

An article in the November 2014 The RPM Report takes an in-depth look at why many sponsors choose not to pursue PRO labeling claims despite the release of FDA's final guidance document on PROs in 2009. Citing sources from a crossection of the industry—including RTI-HS's heads of patient-reported outcomes, Ari Gnanasakthy, MBA, MSc and Carla DeMuro, MS—the article goes on to explain why many feel that the trend is changing for the better.

Download the PDF

 

Related Services:
Staff Members: